ProPhase Labs

Website

ProPhase Labs, Inc.

2 Investors
Biotechnology, Genomics, Consumer Health
UNIONDALE, NY

ProPhase Labs is a diversified company operating in biotechnology, genomics, and consumer health. After a history in consumer products and a recent pivot to COVID-19 testing, the company is now focusing its strategy on the commercialization of advanced health solutions. Its main initiatives include an esophageal cancer diagnostic test and direct-to-consumer whole genome sequencing services.

Products & Team

BE-Smart™ Esophageal Cancer Test

Cancer Diagnostic TestSeed

BE-Smart™ is a diagnostic test designed for the early detection of esophageal cancer in patients who have been diagnosed with Barrett's Esophagus, a pre-cancerous condition. The test analyzes protein expression from a small biopsy sample to assess the patient's risk of progression to cancer.

Value Proposition

It provides clinicians with a tool to better assess the risk of cancer in patients with Barrett's Esophagus, enabling more informed decisions for patient monitoring and potential early intervention.

Pain Points

The company addresses the clinical need for better risk stratification in pre-cancerous conditions, the consumer's curiosity about personal genetics and health predispositions, and the general desire for over-the-counter wellness solutions for energy and vitality.

Utilizes a proprietary method for protein expression analysisIntegrates into existing gastroenterology and pathology clinical workflowsDelivers results to clinicians in under one week
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
UNIONDALE, NY
Primary headquarters

Funding History

Total Raised:
$3.0M
E

Debt Financing, Option to Acquire Offering

July 2025
$6.0M
Target
Use of Proceeds
NONE OTHER THAN SALARY IN NORMAL COURSE
Progress
50%
Raised
$3.0M
Target
$6.0M
#000164117225022239